An Alumni of JLab New York City, Manhattan Biosolutions LLC is working on enhancing natural ability of human immune system to recognize cancer as foreign and activate patient's own systems to defend against malignancies. Intended to improve treatment of cancer with the potential of actually preventing cancer, the firm is working on development of the next-generation immunotherapy device. The company's lead platform is based on the safe, attenuated BCG bacteria targeting mutated cancer driver genes to induce innate and adaptive cancer-specific immune responses and on first-in-class immune activators using attenuated mycobacteria BCG genetically programmed with tumor antigens and immunostimulatory factor to induce innate and adaptive cancer-specific immune responses.
